Fresenius Medical Care AG FME.DE
Composite 57/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 41/100 — a slight mark against it.
Valuation ranks 87/100 — a strong point in its favour. Income ranks 81/100 — a strong point in its favour. Growth ranks 57/100 — a slight point in its favour.
Balance-sheet strength ranks 41/100 — a slight mark against it. Momentum ranks 44/100 — a slight mark against it. Quality ranks 49/100 — a slight mark against it.
What the company does Fresenius Medical Care AG provides dialysis treatment and related services globally, including outpatient clinics, hospital-based services, and medical products such as dialysis machines and pharmaceuticals. The company operates through Care Delivery and Care Enablement segments, serving patients with end-stage renal disease and acute kidney failure.
Key financials Revenue declined -5.5% while EPS fell -17.1%. Margins remain thin: gross 26%, operating 8.1%, net 4.9%. ROE is 7.8%, ROA 3.6%, and ROCE 8.1%. Debt/Equity is 0.78 with net debt/EBITDA at 3.78x and interest coverage of 5.26x.
Stock health Quality score is weak at 42.6, but valuation is attractive at 82.9 percentile. Momentum is mixed: +21.08% over 6 months, RSI(14) at 63.70. Dividend yield is 3.4% with a payout ratio of 44%.
Price vs fair value The stock trades at a **discount** of 29.20% to our fair-value estimate of 56.30 and a **discount** of 0.46% to the analyst 12-month target of 43.78. - Valuation metrics (P/E 13.23, EV/EBITDA 6.20) suggest undervaluation (Valuation 82.9). - Weak quality scores (Quality 42.6) may explain the persistent discount. - Analyst targets cluster near current price, limiting upside (analyst count 17.0). - Recent sector headlines (e.g., Quest Diagnostics) may reflect broader sentiment drag (Motley Fool).
Looking forward Forward P/E of 10.50 and PEG of 0.40 imply potential margin expansion or multiple rerating. FCF yield of 14.1% supports cash returns. Execution on cost controls and revenue growth remains critical to closing the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.